PCAOB audited FY2024 and FY2025 and reviewed unaudited six months ended June 30, 2026 financials of G3 and its consolidated subsidiaries (“G3”) delivered

In FY 2025, the Combined G3 company had consolidated revenue of $108 million and Adjusted EBITDA (non-GAAP) of $5.0 million, as reconciled below

Sufficient working capital obtained to fund Profusa operations for near term and progress continues in converting debt and liabilities to Preferred Stock while also making progress towards obtaining CE mark

Profusa regained compliance with Nasdaq continued listing standards

BERKELEY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (Profusa; Nasdaq: PFSA) (“Profusa”), a digital health company pioneering next-generation biosensor technologies, announced progress towards satisfaction of the conditions to close the Option Agreement (the “Agreement”) with G3 Vision Labs, Inc. (together with its consolidated subsidiaries, “G3”), including receipt of G3’s consolidated PCAOB audited financial statements for FY 2025 and FY 2024 (the “G3 Audited Financial Statements”) and unaudited consolidated financial statements for the six months ended June 30, 2026 (the “G3 Unaudited Financial Statements”).

The previously announced signing of the Agreement provided Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3. Upon exercise of the option and following the closing, the combined company is expected to operate as a public diagnostics company.

Progress towards satisfaction of the conditions to close the Agreement includes:

  • Receipt of the G3 Audited Financial Statements for the years ended December 31, 2024 and 2025 and the G3 reviewed Unaudited Financial Statements as of June 30, 2026.
  • On September 9, 2026, as previously announced, Profusa received a Nasdaq compliance letter, which served to confirm that Profusa had demonstrated compliance with Listing Rules 5550(a)(2) and 5550(b)(1) (the “Bid Price” and “Equity” Rules, respectively). Accordingly, Profusa continues to operate in compliance with Nasdaq rules.
  • Profusa has entered exchange agreements of $10.7 million to date of debt and liabilities, which were exchanged for a newly designated series of non-voting convertible preferred stock (the “Preferred Stock”), with each share of Preferred Stock convertible into 1,000 shares of Profusa common stock after stockholder approval
  • Profusa borrowed $0.7 million in October under its current note agreement with Ascent Partners to fund near-term working capital needs.
  • As previously announced, Profusa continues to make progress towards obtaining CE mark approval for its Lumee Oxygen Platform while effectively managing costs.

“I am very pleased with the timely progress we are making and support we are receiving towards exercising the Option to acquire G3,” stated Executive Chairman and CEO, Jack Stover. “I believe we are on a good track to closing by the end of the year.”

Audited G3 Combined Company Financial Results for FY 2025: 

  • Revenue of the G3 combined company was $108 million
  • G3 combined company net loss was $2.4 million

Unaudited G3 Combined Company non-GAAP Financial Results for FY 2025:

  • G3 combined company EBITDA (non-GAAP) was $7.3 million and Adjusted EBITDA (non-GAAP) was $5.0 million when adjusted for one-time items
Revenue, EBITDA and Adjusted EBITDA FY 2025
Revenue 108,021,457
Net income (loss) (2,380,320)
Add: Income taxes –
Add: Interest expense 3,414,450
Add: Depreciation and amortization 2,933,024
Add: D&A included in cost of revenue 3,336,355
EBITDA 7,303,509
Total one-time items 1 (2,345,670)
Adjusted EBITDA 4,957,839
Adjusted EBITDA Margin 4.6%

1 FY 2025 one-time items include a $2M settlement for the Acutis COVID-19 claim recovery, one-time other income items, and transaction costs related to the Dominion acquisition.         

Use of Non-GAAP Financial Measures

This press release includes financial measures that are not in accordance with GAAP, including EBITDA, Adjusted EBITDA and Adjusted EBITDA margin. The non-GAAP financial information is presented for supplemental informational purposes only and should not be considered a substitute for financial information presented in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies.

About Profusa

Based in Berkeley, California, Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on pioneering next-generation biosensor technologies. Profusa previously announced the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. and its subsidiaries (“G3″). Upon option exercising, the combined company is expected to operate as a public diagnostics company.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

About G3

G3 provides laboratory testing solutions, clinical insight, and reporting tools that help healthcare teams make informed treatment decisions, streamline workflows, and improve patient outcomes. Its CLIA-certified and CAP/CLIA accredited national medical laboratories provide molecular diagnostic tests for infectious disease and urine and blood clinical toxicology testing, with a client base serving addiction treatment, pain management, and behavioral health providers across the country.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the transaction, the conditions to the exercise of the option under the Agreement, Profusa’s strategic plans and the proposed business combination with G3. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, without limitation, risks related to Profusa’s ability to satisfy the conditions of the Agreement and to integrate G3 and its subsidiaries into Profusa’s business, the risk that customer demand may be less than expected, the risks in the business combination that would result from the option exercise, as well as the risks in complying with the representations, warranties and covenants set forth in the Agreement, and risks related to the completion and terms of the contemplated financings, the risk that Profusa does not receive the stockholder approval, the dilutive effect on existing Profusa stockholders of the issuance of shares of common stock and Preferred Stock as consideration for the Agreement and, if the option is exercised, upon conversion of the Preferred Stock, and the risk that G3’s indebtedness is not refinanced, repaid or otherwise satisfied on acceptable terms or at all. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. There are risks and uncertainties described more fully in Profusa’s public filings from time to time with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Investor and Media Contact:

hr@profusa.com

TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce its third-quarter 2026 consolidated operational and financial results. All financial references are denominated in U.S. dollars, unless otherwise noted.

Highlights:

  • Continued Rwanda CORSIA Sales: The Company continues to strategically and opportunistically monetize its CORSIA-eligible1 carbon credits from the Rwanda cookstoves project. During the quarter, the Company received approximately $1.9 million in cash proceeds from sales.
  • CORSIA Eligibility Extended Across Issued Rwanda Credits: During the quarter, Verra completed CORSIA-eligible tagging of 342,356 carbon credits held by the Company and 639,609 carbon credits held by project partner, the DelAgua Group (“DelAgua”), bringing the aggregate number of CORSIA-eligible tagged carbon credits issued from the project to 1,959,812.
  • Positive EU CORSIA Proposal and Pricing Momentum: The European Commission’s proposal embeds CORSIA into European Union law through 2035. CORSIA-eligible carbon credit pricing strengthened significantly during the quarter, with the spot price of the ICE Dec-26 CP1 futures contract increasing approximately 39%2,3.
  • Financial Results: The Company ended the quarter with total assets of approximately $105.8 million, including $2.5 million in cash and cash equivalents, $13.5 million in carbon credit inventory, and $3.3 million in the carbon credit revenue participation asset. The Company reported third-quarter 2026 earnings per share of $0.02 (Q3 2025: $0.02).

“With approximately two million CORSIA-eligible carbon credits now issued from our Rwanda project and a regular semi-annual production cadence, we believe we hold one of the few fully eligible, uncommitted inventories available to the aviation compliance market,” said Michael Costa, Chief Executive Officer of Base Carbon. “Both pricing and volumes traded strengthened significantly during the quarter, and we will continue to monetize our inventories in an opportunistic and accretive manner. In Vietnam, the government continues to advance the Article 6 framework through which our project’s carbon credits may become CORSIA-eligible, and in India our project remains on track for first issuance under the new VM0047 methodology in 2027.”

Financial Highlights:

(in thousands of United States Dollars) September 30, 2026 December 31, 2025
Total assets $    105,792 $    108,936
Total liabilities   8,218   8,445
Total shareholders’ equity   97,574   100,491
     
Breakdown of key assets    
Cash and cash equivalents $      2,484 $       5,691
Carbon credit inventory   13,505   21,229
Current investment in carbon credit projects   32,737   11,041
Carbon credit revenue participation asset   3,324   1,455
Non-current investment in carbon credit projects   51,961   68,146


Rwanda Cookstoves Project

The Company continued to monetize CORSIA-eligible carbon credits generated by its Rwanda cookstoves project, receiving cash proceeds of approximately $1.9 million during the quarter. Following the Government of Rwanda’s submission of its Biennial Transparency Report (“BTR”), Verra completed CORSIA-eligible tagging of 342,356 carbon credits held by the Company, resulting in all carbon credits held in the Company’s inventory being eligible for CORSIA’s First Phase compliance period. In September 2026, following the purchase of the required insurance, Verra completed CORSIA-eligible tagging of 639,609 previously issued carbon credits held by DelAgua pursuant to the project agreement and revenue sharing arrangement.

Subsequent to quarter-end, 387,015 carbon credits were issued from the project, marking the project’s fifth issuance. These carbon credits are held by DelAgua pursuant to the project agreement and revenue sharing arrangement. The Company and DelAgua are pursuing CORSIA-eligible tagging of these carbon credits through inclusion in the Government of Rwanda’s forthcoming BTR submission.

As of the date of this release, the Company holds approximately 0.9 million CORSIA-eligible carbon credits in inventory, with a further approximately 1.1 million carbon credits held by DelAgua, of which approximately 0.7 million are CORSIA-eligible. Going forward, the project is anticipated to generate approximately 2.2 million additional carbon credits on regular 6-month intervals during the remainder of the project’s crediting period, with the next issuance anticipated in the first half of 2027.

Vietnam Household Devices Project

During the quarter, the government of Vietnam continued to make meaningful progress developing its internal carbon market and finalizing its Article 6 and Letter of Authorization (“LOA”) process. Receipt of an LOA would position the project’s carbon credits for potential compliance market eligibility, including CORSIA and Singapore’s carbon tax regime.

Also, during the quarter, the water purifier component of the project was transitioned to Verra’s newest VMR0015 methodology for vintages after 2027, which is expected to reduce carbon credit generation from the water purifier component by approximately 15%. Subject to the receipt of the necessary governmental approvals and the exercise of project expansion rights, the Company now estimates the project could generate approximately 15.3 million carbon credits eligible for international transfer and potential compliance market use.

India Afforestation, Reforestation, and Revegetation (ARR) Project

During the quarter, the Company engaged an independent third-party consultant, Kanop, to conduct the eligibility analysis required for the project’s transition to Verra’s VM0047 methodology and made capital payments of approximately $0.3 million to its project development partner, Value Network Ventures Pte. Ltd. (“VNV”).

During and subsequent to the quarter, VNV continued regular-way replanting activities to continually replenish the project’s standing stock, at no incremental cost to the Company, pursuant to the project agreement. The project remains on track for first carbon credit issuance in 2027 and continues to pursue Verra’s ABACUS label.

About Base Carbon

Base Carbon provides capital, development expertise and management operating resources to projects involved in the global carbon markets. We endeavor to be the preferred carbon project partner in providing capital and management resources to carbon removal and reduction projects globally and, where appropriate, will utilize technologies within the evolving environmental industries to enhance efficiencies, commercial credibility, and trading transparency. For more information, please visit www.basecarbon.com.

Media and Investor Inquiries

Base Carbon Inc.
Investor Relations
Tel: +1 647 952 3979
E-mail: investorrelations@basecarbon.com

Media Inquiries
E-mail: media@basecarbon.com

Cautionary Statement Regarding Forward Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws relating to the focus of Base Carbon’s business, the expected issuance and timing of carbon credits, the expected tagging of CORSIA-eligible carbon credits by Verra, including through the inclusion of carbon credits in the Government of Rwanda’s biennial transparency reporting or the purchase of certain credit insurance, the European Commission’s proposal to embed CORSIA into European Union law and the future application of the EU ETS proposal, Article 6 of the Paris Agreement, the Article 6 Authorized label, the CORSIA-eligible label and the ABACUS label and market reaction thereto, the timing and ability to complete the sale of carbon credits, the outcome of current carbon credit sale processes and the ability to monetize or sell carbon credits and the receipt of proceeds from the disposition of carbon credits or revenue sharing arrangements, the implementation of the CORSIA framework and Singapore’s carbon tax regime and timing of eligibility and participation of carbon credits and carbon credit methodologies thereunder, the market demand and price of CORSIA-eligible carbon credits, the development and finalization of Vietnam’s Article 6 and letter of authorization process, the receipt and timing of a letter of authorization for the Vietnam household devices project and ability to sell carbon credits from such project internationally, the estimated number of carbon credits from the Vietnam household devices project eligible for international transfer, the ability to transition the Vietnam household devices project to methodology VM0050, the application of the VMR0015 methodology to the Vietnam household devices project and the number of carbon credits issuable thereunder, the ability to transition the India afforestation, reforestation, and revegetation project methodology to VM0047 and ability to replant project trees to address tree mortality, the timing of project registration and first carbon credit issuance of the India afforestation, reforestation, and revegetation project and the potential exercise of contractual expansion options for the Vietnam household devices project and the India afforestation, reforestation, and revegetation project. In some cases, but not necessarily in all cases, forward-looking information may be identified by the use of forward-looking terminology such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans”, “seeks” or variations of such words and similar expressions or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events. These statements should not be read as guarantees of future performance, results, or achievements.

Although management believes that the anticipated future results, performance or achievements expressed or implied by the forward-looking information are based upon reasonable assumptions and expectations, readers should not place undue reliance on forward-looking information because it involves assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to differ materially from anticipated future results, performance or achievements expressed or implied by such forward-looking information.

In respect of the Rwanda cookstoves project and the Vietnam household devices project, certain factors that influence the commercial success of such projects, including the timing and number of expected carbon credits, include among other things: (i) the Company has retained industry leading experts/consultants/advisors to assist with the evaluation, planning, negotiation and execution of such projects, (ii) the work product, including monitoring reports, of each project’s validation and verification body, (iii) project carbon credit market prices, (iv) the verification of ongoing project monitoring reports and issuance of carbon credits by Verra, (v) changes to laws, regulation or policies in applicable jurisdictions, and (vi) the Company has sufficient funds on hand to make any required carbon credit purchase price payments.
In respect of the Rwanda cookstoves project and the Vietnam household devices project, certain assumptions that influence the commercial success of such projects, including the timing and number of expected carbon credits, include among other things: (i) distributed cookstoves and water purifiers perform to specification when used and participating households use the devices as contemplated by project estimates, (ii) the Company’s in-country project partners, being DelAgua in the case of the Rwanda cookstoves project and SIPCO and the project offtaker in the case of the Vietnam household devices project, perform their obligations in connection with the development and operation of the projects, (iii) the new project methodologies are applied to the projects and there is no further changes in the project methodologies used by the applicable carbon credit registry or otherwise adopted by project proponents which results in less carbon credits being issuable, (iv) positive market recognition of the attributes linked to the Company’s carbon credits (such as project methodologies and changes thereto) and acceptance of such carbon credits by emissions trading schemes or compliance programs such as CORSIA or Singapore’s carbon tax regime, (v) continued participant involvement and public support, including that of applicable governmental authorities, of the voluntary and compliance carbon markets, and (vi) counterparties to carbon credit sale agreements perform their obligations, including payment of the purchase price on settlement.

In respect of the India afforestation, reforestation, and revegetation project, certain factors that influence the commercial success of the project include, among other things: (i) the Company’s expertise with respect to the evaluation, planning and negotiation of the project, (ii) the conduct of the project counterparties, including cooperation with local small-land owners, (iii) project costs and carbon credit market prices, (iv) ongoing project monitoring and issuance of carbon credits by Verra, (v) changes to laws and regulation in the Republic of India, and (vi) tree mortality rates, including due to extreme weather event and natural disasters.

In respect of the India afforestation, reforestation, and revegetation project, certain assumptions that influence the commercial success of the project include, among other things: (i) the development of the project remains in line with anticipated timelines and costs, (ii) project counterparties, including project partner Value Network Ventures Pte. Ltd., its subcontractors and local small-land owners, perform their contractual and/or standard operating procedures, (iii) the survival of trees, (iv) the successful project validation and registration by Verra, (v) the waiver of any carbon credit ownership rights by local project participants, (vi) the growth rates of trees are consistent with the expectations under the project which is then reflected by monitoring reports accepted by Verra, (vii) the Company has sufficient funds to satisfy its capital commitments, (viii) over the life of the project, there is no change to the project methodology which results in less carbon credits being issuable from the operation of such project, and (ix) continued participant involvement and public support of the voluntary carbon market.

The forward-looking statements made herein are subject to a variety of risk factors and uncertainties, many of which are beyond the Company’s control, which could cause actual events or results to differ materially and adversely from those reflected in the forward-looking statements. Readers are cautioned that forward-looking statements are not guarantees of future performance. Specific reference is made to the management’s discussion and analysis for the Company’s three and nine months ended September 30, 2026 and the most recent Annual Information Form on file with the Canadian provincial securities regulatory authorities (and available on www.sedarplus.ca) for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect the Company’s ability to achieve the expectations set forth in the forward-looking statements contained in this press release.

Should one or more of the risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual events or results may vary materially and adversely from those described in the forward-looking information. The forward-looking information contained in this press release is provided as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

                                                                         

1 Carbon Offsetting and Reduction Scheme for International Aviation (“CORSIA”) and CORSIA – First Phase, 2024-2026 Eligible (“CORSIA-eligible”).

2 Refer to July 21, 2026, press release for more information.

3 ICE Futures Europe CORSIA Eligible Emissions Units (2024-2026) Futures, available at ice.com.

WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Monday November 16 at 10:30 AM GMT (5:30 AM ET), Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

Positive Operating Cash Flow and Improved Segment Profitability Reflect Disciplined Execution
New Product Innovation Drives Consumer Engagement Across Channels

GRAPEVINE, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Solo Brands, Inc. (OTCQB: SBDS) (“Solo Brands” or “the Company”), a premium outdoor lifestyle company that develops and markets branded products across its Solo Stove, Chubbies, and Watersports segments, today announced its financial results for the three and nine months ended September 30, 2026.

John Larson, President and Chief Executive Officer, commented, “While the third quarter is typically our seasonally smallest sales quarter, we continued to make measurable progress strengthening the business. We improved segment profitability, generated more than $6 million of operating cash flow, and further advanced our transformation strategy through disciplined execution, cost management, and operational efficiency initiatives. These results reflect our continued focus on building a more resilient, leaner cash-generative company.

“While revenue performance remains below our expectations, we are encouraged by improving consumer engagement and the strong response to recent product innovation. Products launched over the past year for our Solo Stove segment represented nearly half of our website sales during the quarter, highlighting the strength of our innovation pipeline and the value of our brand portfolio. We are also expanding how we engage consumers through influencer-led marketing, social commerce initiatives, and platforms such as TikTok Shop, helping us reach new audiences and build deeper customer connections. As we enter holiday 2026 with a leaner inventory position, strong liquidity, and growing momentum in our newest products, we remain focused on driving sustainable growth, profitability, and long-term shareholder value.”

Consolidated Third Quarter 2026 Highlights Compared to Third Quarter 2025

  • Net sales of $43.7 million decreased 17.6% from $53.0 million, primarily the result of the decrease in net sales across our reportable segments.
  • Gross profit of $27.7 million, or 63.4% of net sales, compared to $31.8 million, or 60.0% of net sales. Adjusted gross profit(1) of $28.2 million, or 64.4% of net sales, compared to $32.2 million, or 60.6% of net sales. Gross profit was impacted by lower net sales and changes in channel mix, partially offset by reduced promotional activity and tariff impacts compared to the prior year period.
  • Operating expenses of $42.1 million decreased 12.3% from $48.0 million.
    • Selling, general & administrative expenses of $31.6 million decreased 20.0% from $39.5 million, primarily due to lower payroll and related costs, reduced marketing spend within the Solo Stove segment, and lower variable costs associated with lower DTC net sales, reflecting disciplined expense management across the business.
    • Restructuring, contract termination and impairment charges were $6.0 million compared to $1.9 million, primarily reflecting non-cash impairments and one-time costs from streamlining our fulfillment footprint and exiting underperforming operations.
  • Net loss attributable to Solo Brands, Inc. of $20.8 million, or $8.08 diluted loss per share of Class A common stock(2), compared to $15.0 million, or $9.22 diluted loss per share of Class A common stock(2).
  • Adjusted net loss attributable to Solo Brands, Inc.(1) of $11.6 million, or $4.51 adjusted diluted loss per share of Class A common stock(1)(2), compared to $7.1 million, or $4.33 adjusted diluted loss per share of Class A common stock(1)(2).
  • Adjusted EBITDA(1) of $(2.1) million, or (4.9)% of net sales, improved from $(5.1) million, or (9.6)% of net sales.

Segment Third Quarter 2026 Highlights Compared to Third Quarter 2025

Solo Stove

  • Net sales of $24.7 million decreased 19.9%, reflecting lower unit volumes in core fire pits partially mitigated by new product introductions, as well as softness in the retail channel.
  • Segment adjusted EBITDA of $2.3 million, or 9.4% of net sales, compared to $1.4 million, or 4.4% of net sales, reflecting the benefit of ongoing cost reduction initiatives, including leaner operations, payroll, and marketing, amid lower net sales.

Chubbies

  • Net sales of $13.7 million decreased 16.8%, reflecting variability in customer demand within both the DTC and retail channels.
  • Segment adjusted EBITDA of $0.2 million, or 1.2% of net sales, compared to $(1.2) million, or (7.5)% of net sales, primarily reflecting the benefit of cost reduction initiatives including leaner operations and payroll, partially offset by lower gross profit on the decrease in net sales.

Watersports

  • Net sales of $5.3 million decreased 7.4%, reflecting softer sales on less promotional activity within the DTC channel, partially offset by increased customer demand within the retail channel.
  • Segment adjusted EBITDA of $0.5 million, or 8.9% of net sales, compared to $0.5 million, or 8.3% of net sales.

Consolidated Nine Months Ended September 30, 2026 Highlights Compared to Nine Months Ended September 30, 2025

  • Net sales of $195.1 million decreased 12.4% from $222.5 million, primarily the result of the decrease in both DTC and retail channel net sales within the Solo Stove segment, and, to a lesser extent, declines in both channels within the Chubbies segment, partially offset by an increase in retail channel sales within our Watersports segment.
  • Gross profit of $113.6 million, or 58.3% of net sales, compared to $131.1 million, or 58.9% of net sales. Adjusted gross profit(1) of $116.0 million, or 59.5% of net sales, compared to $131.9 million, or 59.3% of net sales. Gross profit was impacted by lower net sales, changes in channel and product mix, and a raw material inventory write-off related to the closure of Oru’s manufacturing facility, partially offset by reduced promotional activity and tariff impacts compared to the prior year period.
  • Operating expenses of $129.3 million decreased 22.9% from $167.7 million.
    • Selling, general & administrative expenses of $107.4 million decreased 14.9% from $126.2 million, primarily due to lower payroll and related costs, reduced marketing spend within the Solo Stove segment, and lower variable costs associated with lower DTC net sales, reflecting disciplined expense management across the business.
    • Restructuring, contract termination and impairment charges were $8.2 million compared to $18.0 million, as lower consulting, retention, and severance costs were partially offset by non-cash impairments from closing distribution centers, Oru’s manufacturing facility, and an underperforming retail store operation.
  • Net loss attributable to Solo Brands, Inc. of $30.6 million, or $12.03 diluted loss per share of Class A common stock(2), compared to $40.7 million, or $26.59 diluted loss per share of Class A common stock(2).
  • Adjusted net loss attributable to Solo Brands, Inc.(1) of $15.2 million, or $5.96 adjusted diluted loss per share of Class A common stock(1)(2), compared to $11.8 million, or $7.71 adjusted diluted loss per share of Class A common stock(1)(2).
  • Adjusted EBITDA(1) of $13.0 million, or 6.6% of net sales, improved from $8.9 million, or 4.0% of net sales.

Segment Nine Months Ended September 30, 2026 Highlights Compared to Nine Months Ended September 30, 2025

Solo Stove

  • Net sales of $73.4 million decreased 22.9%, reflecting lower unit volumes in core fire pits partially mitigated by new product introductions, as well as softness in the retail channel.
  • Segment adjusted EBITDA of $4.3 million, or 5.9% of net sales, compared to $3.3 million, or 3.4% of net sales, primarily reflecting the benefit of ongoing cost reduction initiatives, including leaner operations, payroll, and marketing, amid lower net sales and, to a lesser extent, reduced promotional activity compared to the prior year period.

Chubbies

  • Net sales of $91.0 million decreased 12.2%, reflecting variability in customer demand within both the DTC and retail channels.
  • Segment adjusted EBITDA of $20.2 million, or 22.2% of net sales, compared to $21.5 million, or 20.8% of net sales, reflecting lower gross profit on the decrease in net sales, partially offset by the benefit of cost reduction initiatives, including leaner operations and payroll.

Watersports

  • Net sales of $30.6 million increased 32.4%, reflecting an expanded partnership with a key customer within the retail channel, partially offset by softer sales on less promotional activity within the DTC channel.
  • Segment adjusted EBITDA of $5.3 million, or 17.4% of net sales, compared to $2.8 million, or 12.3% of net sales, reflecting the higher net sales during the period and the benefit of cost reduction initiatives, specifically payroll and marketing.

Consolidated Balance Sheet

Cash and cash equivalents were $40.2 million as of September 30, 2026 compared to $20.0 million as of December 31, 2025.

Inventory was $59.2 million as of September 30, 2026, a decrease from $81.6 million as of December 31, 2025, primarily reflecting continued supply chain consolidation and tight working capital management that enabled the rightsizing of inventory to meet DTC and retail channel demand.

Outstanding borrowings(3) were $264.4 million, including interest paid-in-kind, under the 2025 Term Loan (as defined herein) as of September 30, 2026, and no outstanding borrowings under the 2025 Revolving Credit Facility (as defined herein) as of September 30, 2026. As of September 30, 2026, availability for future draws under the 2025 Revolving Credit Facility, based on the borrowing base as of such date, was $50.3 million, net of issued letters of credit.

Full Year 2026 Outlook(4)

We are updating our 2026 financial guidance, which includes the lower end of our original guidance range, based on our nine-month results and current outlook as follows:

  • Net sales are expected to be between $270 million and $290 million for 2026.
  • Adjusted EBITDA(1)(5) is expected to be between $21 million and $25 million for 2026.
   
(1) This press release includes references to non-GAAP financial measures. Refer to “Non-GAAP Financial Measures” later in this press release for the definitions of the non-GAAP financial measures presented and a reconciliation of these measures to their closest comparable GAAP measures.
   
(2) Effective January 1, 2026, the Company completed a series of transactions which, among other things, resulted in all outstanding Class B common stock being cancelled and exchanged for Class A common stock on a one-for-one basis (the “Corporate Simplification”). See our 2026 Q1 Form 10-Q for additional details regarding the Corporate Simplification.
   
(3) On June 13, 2025, the Company entered into an amendment (the “2025 Credit Agreement”) to its existing credit agreement. The 2025 Credit Agreement consists of (i) a term loan with an aggregate principal amount of $240 million (“2025 Term Loan”) and (ii) a revolving credit facility with an initial committed amount of $90 million (“2025 Revolving Credit Facility”). The 2025 Revolving Credit Facility includes (i) a sub-limit of $10 million for swing line loans and (ii) a separate sub-limit of $20 million for the issuance of letters of credit. See our 2025 Form 10-K for additional details regarding the 2025 Credit Agreement.
   
(4) The Company’s full year 2026 guidance is based on a number of assumptions that are subject to change and many of which are outside the Company’s control. If actual results vary from these assumptions, the Company’s expectations may change. There can be no assurance that the Company will achieve these results.
   
(5) The Company has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted GAAP net income (loss) within this press release because the Company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, equity-based compensation with respect to future grants and forfeitures, which could materially affect the computation of forward-looking GAAP net income, and are inherently uncertain and depend on various factors, some of which are outside of the Company’s control.
   

Conference Call Details

A conference call to discuss the Company’s third quarter 2026 results is scheduled for November 12, 2026, at 9:00 a.m. ET. Investors and analysts who wish to participate in the call are invited to dial 1-866-652-5200 (international callers, please dial 1-412-317-6060) approximately 10 minutes prior to the start of the call. A live webcast of the conference call will be available in the investor relations section of the Company’s website, https://investors.solobrands.com.

A recorded replay of the call will be available shortly after the conclusion of the call and remain available until November 19, 2026. To access the telephone replay, dial 1-855-669-9658 (international callers, please dial 1-412-317-0088). The access code for the replay is 8833822. A replay of the webcast will also be available shortly after the conclusion of the call and will remain available for one year.

About Solo Brands, Inc.

Solo Brands is a premium outdoor lifestyle company that develops and markets branded products designed to enhance outdoor recreation, entertainment, and adventure while bringing people together. The Company operates across three primary outdoor lifestyle categories – Solo Stove, known for its highly rated fire pits, griddles, coolers, and accessories; Chubbies, a lifestyle brand focused on casual wear, activewear, and swimwear; and Watersports, which includes ISLE, a maker of inflatable and hard paddle boards and related accessories, and Oru Kayak, the innovator of origami-inspired folding kayaks. Headquartered in Grapevine, Texas, Solo Brands employs approximately 300 associates. Its products are sold through leading retailer partners, direct-to-consumer channels, and a growing network of distributors worldwide. For a listing of our brands and more information, please visit https://solobrands.com.

Contacts:

Mark Anderson, Senior Director of Treasury & Investor Relations
Investors@solobrands.com

Three Part Advisors, LLC
Sandy Martin: smartin@threepa.com, 214-616-2207
Steven Hooser: shooser@threepa.com, 214-872-2710

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our financial outlook for 2026, sales trends, our strategic transformation initiatives and related impacts, including increasing consumer engagement, expanding brand awareness and introducing new products, leveraging our intellectual property portfolio, our future financial position and plans for revenue growth, turnaround efforts and business strategy, and related impacts to future financial results. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “guidance,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our future ability to continue as a going concern; our ability to realize expected benefits from our strategic plans; our ability to implement any restructuring and cost-reduction efforts; our limited liquidity; our ability to mitigate the impact of new and increased tariffs and similar restrictions on our business; our reliance on third-party manufacturers, which operate mostly outside of the U.S., and problems with, or the loss of, our suppliers or an inability to obtain raw materials; our dependence on cash generated from operations to support our business and our growth initiatives; our ability to relist to a national exchange; risks associated with fluctuations in the price of our Class A common stock; risks associated with our indebtedness, including the limits imposed by our indebtedness to invest in the ongoing needs of our business; our ability to maintain and strengthen our brand to generate and maintain ongoing demand for our products; our ability to design, develop and introduce new products; our ability to manage our future growth effectively; our ability to expand into additional markets; risks associated with our international operations; our inability to sustain historic growth rates; our ability to cost-effectively attract new customers and retain our existing customers; the highly competitive market in which we operate; our failure to maintain product quality and product performance at an acceptable cost; the impact of product liability and warranty claims and product recalls, including write-offs; geopolitical actions, natural disasters, or pandemics; the ability of our largest stockholders to influence corporate matters. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings we make with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements speak only as of the date the statements are made and are based on information available to Solo Brands at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Availability of Information on Solo Brands’ Website and Social Media Profiles

Investors and others should note that Solo Brands routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Solo Brands investors website at https://investors.solobrands.com. We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public. While not all of the information that the Company posts to the Solo Brands investors website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Solo Brands to review the information that it shares at the “Investors” link located at the top of the page on https://solobrands.com and to regularly follow our social media profiles. Users may automatically receive email alerts and other information about Solo Brands when enrolling an email address by visiting “Investor Email Alerts” in the “Resources” section of Solo Brands’ investor website at https://investors.solobrands.com.

Social Media Profiles:

https://linkedin.com/company/solo-brands/
https://instagram.com/solobrands/
https://www.facebook.com/groups/368095467245044/

SOLO BRANDS, INC.
Consolidated Statements of Operations
(Unaudited)
 
    Three Months Ended September 30,   Nine Months Ended September 30,  
(In thousands, except per share data) 2026   2025   2026   2025  
Net sales $ 43,719     $ 53,038     $ 195,060     $ 222,547    
Cost of goods sold   16,003       21,192       81,422       91,497    
Gross profit   27,716       31,846       113,638       131,050    
Operating expenses                
  Selling, general & administrative expenses   31,596       39,495       107,410       126,171    
  Depreciation and amortization expenses   4,180       5,824       12,622       19,107    
  Restructuring, contract termination and impairment charges   6,041       1,940       8,241       18,030    
  Other operating expenses   320       764       1,010       4,397    
  Total operating expenses   42,137       48,023       129,283       167,705    
Income (loss) from operations   (14,421 )     (16,177 )     (15,645 )     (36,655 )  
Non-operating (income) expense                
  Interest expense, net   7,504       7,556       22,884       19,115    
  Other non-operating (income) expense   (53 )     (255 )     (320 )     2,432    
  Total non-operating (income) expense   7,451       7,301       22,564       21,547    
  Income (loss) before income taxes   (21,872 )     (23,478 )     (38,209 )     (58,202 )  
  Income tax expense (benefit)   (1,118 )     (552 )     (7,598 )     4,068    
Net income (loss)   (20,754 )     (22,926 )     (30,611 )     (62,270 )  
  Less: net income (loss) attributable to noncontrolling
interests
  —       (7,900 )     —       (21,584 )  

Net income (loss) attributable to Solo Brands, Inc.
$ (20,754 )   $ (15,026 )   $ (30,611 )   $ (40,686 )  
                   

Net income (loss) per share of Class A common stock
               
  Basic and diluted(1) $ (8.08 )   $ (9.22 )   $ (12.03 )   $ (26.59 )  
                   

Weighted-average Class A common stock outstanding
               
  Basic and diluted(1)   2,569       1,629       2,546       1,530    
                                   
(1) Effective January 1, 2026, the Company completed a series of transactions which, among other things, resulted in all outstanding Class B common stock being cancelled and exchanged for Class A common stock on a one-for-one basis. See our 2026 Q1 Form 10-Q for additional details regarding the Corporate Simplification.
   

SOLO BRANDS, INC.
Segment Operating Results
(Unaudited)
 
  Three Months Ended September 30, 2026   Three Months Ended September 30, 2025  
(in thousands) Solo Stove   Chubbies   Watersports   Solo Stove   Chubbies   Watersports  
Net sales $ 24,673   $ 13,705   $ 5,341   $ 30,792   $ 16,478     $ 5,768  
Cost of goods sold   9,457     4,031     2,344     11,958     6,592       2,642  
Marketing expense   4,377     2,957     826     6,676     2,928       824  
Employee-related compensation   1,902     2,123     253     2,348     3,210       491  
Other segment operating expenses   6,606     4,432     1,440     8,447     4,979       1,331  
Segment adjusted EBITDA $ 2,331   $ 162   $ 478   $ 1,363   $ (1,231 )   $ 480  
                                       

    Nine Months Ended September 30, 2026   Nine Months Ended September 30, 2025  
(in thousands) Solo Stove   Chubbies   Watersports   Solo Stove   Chubbies   Watersports  
Net sales $ 73,383   $ 91,028   $ 30,649   $ 95,218   $ 103,622   $ 23,141  
Cost of goods sold(1)   28,001     33,421     18,405     37,158     42,591     11,189  
Marketing expense   15,456     11,709     2,389     21,476     10,453     2,776  
Employee-related compensation   5,882     7,385     915     8,471     10,054     1,993  
Other segment operating expenses   19,751     18,266     3,611     24,842     18,983     4,342  
  Segment adjusted EBITDA $ 4,293   $ 20,247   $ 5,329   $ 3,271   $ 21,541   $ 2,841  
                                       
(1) Cost of goods sold excludes $1.6 million of inventory charges associated with restructuring and consolidation activities for the nine months ended September 30, 2026, largely the result of a $1.4 million inventory writedown of raw materials related to the closure of the Oru manufacturing facility within the Watersports segment, as these charges are not considered a component of segment adjusted EBITDA.
                                       

SOLO BRANDS, INC.
Consolidated Balance Sheets
(Unaudited)
 
(In thousands, except number of shares and par value) September 30,
2026
  December 31,
2025
 
ASSETS        
Current assets        
  Cash and cash equivalents $ 40,197     $ 20,034    
  Accounts receivable, net of allowance for credit losses of $0.5 million and $1.1 million as of September
30, 2026 and December 31, 2025, respectively
  12,798       29,764    
  Inventory   59,242       81,648    
  Prepaid expenses and other current assets   10,645       8,582    
  Total current assets   122,882       140,028    
Non-current assets        
  Property and equipment, net   8,391       13,197    
  Intangible assets, net   93,601       100,837    
  Goodwill   73,119       73,119    
  Operating lease right-of-use assets   10,983       17,901    
  Other non-current assets   13,853       15,260    
  Total non-current assets   199,947       220,314    
  Total assets $ 322,829     $ 360,342    
           
LIABILITIES AND SHAREHOLDERS’ EQUITY        
Current liabilities        
  Accounts payable $ 11,076     $ 13,073    
  Accrued expenses and other current liabilities   21,283       30,843    
  Deferred revenue   1,184       1,649    
  Current portion of long-term debt   6,600       1,800    
  Total current liabilities   40,143       47,365    
Non-current liabilities        
  Long-term debt, net   249,798       240,272    
  Deferred tax liability   211       6,739    
  Operating lease liabilities   9,691       13,888    
  Other non-current liabilities   1,018       677    
  Total non-current liabilities   260,718       261,576    
           
Commitments and contingencies        
           
Shareholders’ equity        
  Class A common stock, par value $0.001 per share; 475,000,000 shares authorized; 2,580,074 and
1,847,618 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively(1)
  3       2    
  Class B common stock, par value $0.001 per share; 50,000,000 shares authorized; 0 and 674,319 shares
issued and outstanding as of September 30, 2026 and December 31, 2025, respectively(1)
  —       1    
  Additional paid-in capital   384,249       377,331    
  Retained earnings (accumulated deficit)   (360,576 )     (329,965 )  
  Accumulated other comprehensive income (loss)   (488 )     (274 )  
  Treasury stock, 57,522 and 32,836 owned as of September 30, 2026 and December 31, 2025, respectively   (1,220 )     (1,092 )  
  Equity attributable to Solo Brands, Inc.   21,968       46,003    
  Equity attributable to noncontrolling interests   —       5,398    
  Total equity   21,968       51,401    
  Total liabilities and equity $ 322,829     $ 360,342    
                   
(1) Effective January 1, 2026, the Company completed a series of transactions which, among other things, resulted in all outstanding Class B common stock being cancelled and exchanged for Class A common stock on a one-for-one basis. See our 2026 Q1 Form 10-Q for additional details regarding the Corporate Simplification.
   

SOLO BRANDS, INC.
Consolidated Statements of Cash Flows
(Unaudited)
 
  Nine Months Ended September 30,  
(In thousands) 2026   2025  
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss) $ (30,611 )   $ (62,270 )  
Adjustments to reconcile net income (loss) to net cash and cash equivalents (used in) provided by
operating activities
       
Depreciation and amortization   15,926       19,927    
Interest expense payable in kind   11,900       7,138    
Noncash operating lease expense   4,609       5,855    
Amortization of debt issuance costs   4,598       2,059    
Equity-based compensation, net   1,520       1,833    
Loss on disposition of the TerraFlame manufacturing operations   —       1,516    
Other   66       861    
Inventory charges associated with restructuring and consolidation activities   1,594       —    
Restructuring, contract termination and impairment charges   2,690       (220 )  
Change in fair value of contingent consideration   —       (787 )  
Deferred income taxes   (6,528 )     (1,097 )  
Changes in assets and liabilities        
Accounts receivable   16,961       22,442    
Inventory   20,633       24,180    
Prepaid expenses and other current assets   (912 )     1,036    
Accounts payable   (2,173 )     (57,597 )  
Accrued expenses and other current liabilities   (10,219 )     (13,759 )  
Deferred revenue   (465 )     (639 )  
Operating lease liabilities   (3,766 )     (4,652 )  
Other non-current assets and liabilities   198       1,155    
Net cash provided by (used in) operating activities   26,021       (53,019 )  
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditures   (5,040 )     (9,590 )  
Net cash provided by (used in) investing activities   (5,040 )     (9,590 )  
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from revolving credit facilities and term loans   15,000       277,322    
Repayments of revolving credit facilities and term loans   (15,600 )     (189,322 )  
Debt issuance costs paid   —       (18,502 )  
Net consideration paid to Former Sellers of TerraFlame   —       (2,500 )  
Surrender of stock to settle taxes on restricted stock awards   (128 )     (223 )  
Net cash provided by (used in) financing activities   (728 )     66,775    
Effect of exchange rate changes on cash   (90 )     188    
Net change in cash and cash equivalents   20,163       4,354    
Cash and cash equivalents balance, beginning of period   20,034       11,980    
Cash and cash equivalents balance, end of period $ 40,197     $ 16,334    
                 

Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”); however, management believes that certain non-GAAP financial measures provide users of our financial information with useful supplemental information that enables a better comparison of our performance across periods. We use adjusted gross profit, adjusted gross profit margin, adjusted net income, adjusted net income (loss) per Class A common stock, adjusted EBITDA and adjusted EBITDA margin as non-GAAP financial measures, because we believe they are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as measures of our operating performance and believes that these non-GAAP measures are useful to our investors because they are frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. Our management also uses these non-GAAP measures for planning purposes, including the preparation of our annual operating budget and financial projections.

None of these non-GAAP measures is a measurement of financial performance under U.S. GAAP. These non-GAAP measures should not be considered in isolation or as a substitute for a measure of our liquidity or operating performance prepared in accordance with U.S. GAAP and are not indicative of net income (loss) as determined under U.S. GAAP. In addition, the exclusion of certain gains or losses in the calculation of non-GAAP financial measures should not be construed as an inference that these items are unusual or infrequent as they may recur in the future, nor should it be construed that our future results will be unaffected by unusual or non-recurring items. These non-GAAP financial measures have limitations that should be considered before using these measures to evaluate our liquidity or financial performance. Some of these limitations are as follows.

These non-GAAP measures exclude certain tax payments that may require a reduction in cash available to us; do not reflect our cash expenditures, or future requirements, for capital expenditures (including capitalized software development costs) or contractual commitments; do not reflect changes in, or cash requirements for, our working capital needs; do not reflect the cash requirements necessary to service interest or principal payments on our debt; exclude certain purchase accounting adjustments related to acquisitions; and exclude equity-based compensation expense, which has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy.

In addition, other companies may define and calculate similarly-titled non-GAAP financial measures differently than us, thereby limiting the usefulness of these non-GAAP financial measures as a comparative tool. Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other U.S. GAAP-based financial performance measures.

Adjusted Net Income (Loss)

We calculate adjusted net income (loss) as net income (loss) excluding restructuring, contract termination and impairment charges and other costs that are believed by management to be non-operating in nature and not representative of the Company’s core operating performance, as listed below under “Non-GAAP Adjustments”. Adjusted net income (loss) attributable to noncontrolling interests is calculated as income (loss) before income taxes, adjusted in the same manner as adjusted net income (loss), adjusted for the allocable attribution to the noncontrolling interest (when applicable).

Adjusted Net Income (Loss) per Share of Class A Common Stock

We calculate adjusted net income (loss) per share of Class A common stock as adjusted net income (loss), as defined above, less the allocable portion of net income to the noncontrolling interest, divided by weighted average diluted shares or weighted average shares of Class A common stock, respectively, as calculated under U.S. GAAP.

EBITDA

We calculate EBITDA as net income (loss) before interest expense, income taxes, and depreciation and amortization expenses.

Adjusted EBITDA

We calculate adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization expenses, restructuring, contract termination and impairment charges, equity-based compensation expense, and other costs that are believed by management to be non-operating in nature and not representative of the Company’s core operating performance, as listed below under “Non-GAAP Adjustments”.

Adjusted EBITDA Margin

We calculate adjusted EBITDA margin as adjusted EBITDA, divided by net sales.

Adjusted Gross Profit

We calculate adjusted gross profit as gross profit, plus inventory charges associated with restructuring and consolidation activities, inventory fair value write-ups and depreciation and amortization recognized within cost of goods sold.

Adjusted Gross Profit Margin

We calculate adjusted gross profit margin as adjusted gross profit, divided by net sales.

Non-GAAP Adjustments

In addition to the costs specifically noted under the non-GAAP metrics above, the Company believes that evaluation of its financial performance can be enhanced by a supplemental presentation of results that exclude costs believed by management to be non-operating in nature and not representative of the Company’s core operating performance. These costs are excluded in order to provide a basis for evaluating operating results in future periods.

  • Inventory charges associated with restructuring and consolidation activities – primarily represents the inventory writedown of raw materials related to the closure of the Oru manufacturing facility, which was the Company’s only remaining manufacturing operation.
  • Restructuring, contract termination, impairment and related charges – for 2026, represents charges related to impairment of long-lived assets, charges related to cost saving initiatives, such as reduction in force, closure of distribution centers, retention payments to key personnel, closure and impairment of a manufacturing facility, as well as costs related to the engagement of strategic consulting firms for operational planning, legal entity reorganizations, and additional cost saving initiative identification. For 2025, represents charges related to impairment of long-lived assets, cost saving initiatives, such as the reduction in force, closure of distribution centers, owned retail store lease terminations, impairments and modifications, termination of underperforming licensing arrangements and other contracts, retention payments to key personnel, as well as costs related to the engagement of strategic consulting firms for operational planning, legal entity reorganizations, additional cost saving initiative identification and internal management reporting optimization.
  • Amortization expense – represents the non-cash amortization of the following:
    • intangible assets related to the reorganization transactions and acquisitions, and additions to patents in regard to their defense;
    • website development costs; and
    • capitalized software.
  • Depreciation expense – represents the non-cash depreciation of property and equipment.
  • Business optimization and expansion expenses – represents costs related to the engagement of strategic consulting firms for business optimization and expansion planning, and the transaction with the former sellers of TerraFlame in 2025.
  • Costs associated with the refinancing amendment – represents costs related to the engagement of strategic consulting firms in conjunction with the 2025 debt refinancing.
  • Equity-based compensation expense – represents the non-cash expense related to the incentive units, restricted stock units, options, performance stock units, special performance stock units, executive performance stock units and employee stock purchases, with vesting occurring over time and settled with the Company’s Class A common stock. Forfeitures are recognized in the period incurred and reflected as a reduction of the non-cash expense previously recognized for awards not yet vested.
  • Transaction costs – represents costs for professional service fees incurred in connection with potential and completed registered securities offerings, merger, acquisition and/or divestiture activities, and tariff refund specialists.
  • Changes in fair value of contingent earn-out liability – represents the charge to mark the contingent earn-out consideration to fair value in connection with the prior period acquisitions.
  • Management transition costs – represents costs primarily related to executive transition costs for executive search fees and related costs for the transition of certain members of management, such as severance costs.
  • Tax impact of adjusting items – for 2026, reflects no tax effect because of the impacts of the Corporate Simplification and valuation allowance. For 2025, represents the tax impact of the respective adjustments for each non-GAAP financial measure calculated at an expected statutory rate of 21.0%, adjusted to reflect the allocation to the controlling interest.
  • Prior period tax refund received – represents a tax refund received and recorded in the current period related to a prior period.
  • Reversal of valuation allowance – represents the removal of the valuation allowance recorded within the period, as determined through revision of the current period tax provision to reflect the non-GAAP adjustments to income (loss) before income taxes.

SOLO BRANDS, INC.
Reconciliation of Consolidated Non-GAAP Financial Information to GAAP
(Unaudited) (In thousands, except per share amounts)

Adjusted Gross Profit

The following table reconciles gross profit to adjusted gross profit for the periods presented:

  Three Months Ended September 30,   Nine Months Ended September 30,  
(Dollars in thousands) 2026   2025   2026   2025  
Gross profit $ 27,716     $ 31,846     $ 113,638     $ 131,050    
Inventory charges associated with restructuring and
consolidation activities
  170       —       1,594       —    
Depreciation and amortization within cost of goods sold   267       304       753       820    
Adjusted gross profit $ 28,153     $ 32,150     $ 115,985     $ 131,870    
                 
Gross profit margin (Gross profit as a % of net sales)   63.4 %     60.0 %     58.3 %     58.9 %  
                 
Adjusted gross profit margin (Adjusted gross profit as a % of
net sales)
  64.4 %     60.6 %     59.5 %     59.3 %  
                                 

Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share of Class A Common Stock

The following table reconciles net income (loss) to adjusted net income (loss) for the periods presented:

    Three Months Ended September 30,   Nine Months Ended September 30,  
(In thousands, except per share data) 2026   2025   2026   2025  
Net income (loss) $ (20,754 )   $ (22,926 )   $ (30,611 )   $ (62,270 )  
  Restructuring, contract termination, impairment and related
charges
  6,211       1,940       9,835       18,030    
  Amortization expense   3,741       5,456       11,173       15,381    
  Business optimization and expansion expense   274       788       488       4,341    
  Costs associated with the refinancing amendment   —       —       —       4,341    
  Equity-based compensation expense   392       861       1,520       895    
  Transaction costs   46       (25 )     522       (25 )  
  Management transition costs   —       88       —       208    
  Changes in fair value of contingent earn-out liability   —       —       —       (787 )  
  Prior period tax refund received   (1,491 )     —       (1,491 )     —    
  Reversal of valuation allowance(1)   —       3,263       (6,598 )     8,724    
  Tax impact of adjusting items(1)   —       (1,307 )     —       (5,927 )  
Adjusted net income (loss) $ (11,581 )   $ (11,862 )   $ (15,162 )   $ (17,089 )  
  Less: adjusted net income (loss) attributable to
noncontrolling interests
  —       (4,804 )     —       (5,288 )  
Adjusted net income (loss) attributable to Solo Brands,
Inc.
$ (11,581 )   $ (7,058 )   $ (15,162 )   $ (11,801 )  
                   
Net income (loss) per share of Class A common stock(2) $ (8.08 )   $ (9.22 )   $ (12.03 )   $ (26.59 )  
                   
Adjusted net income (loss) per share of Class A common
stock
(2)
$ (4.51 )   $ (4.33 )   $ (5.96 )   $ (7.71 )  
                   
Weighted-average Class A common stock outstanding –
basic and diluted
(2)
  2,569       1,629       2,546       1,530    
                                   
(1)
See our 2026 Q1 Form 10-Q Provision for Income Taxes section for additional details regarding the Corporate Simplification.
                                   
(2)
Effective January 1, 2026, the Company completed a series of transactions which, among other things, resulted in all outstanding Class B common stock being cancelled and exchanged for Class A common stock on a one-for-one basis. See our 2026 Q1 Form 10-Q for additional details regarding the Corporate Simplification.
                                   

Adjusted EBITDA

The following table reconciles net income (loss) to adjusted EBITDA for the periods presented:

  Three Months Ended September 30,   Nine Months Ended September 30,  
(Dollars in thousands) 2026   2025   2026   2025  
Net income (loss) $ (20,754 )   $ (22,926 )   $ (30,611 )   $ (62,270 )  
Interest expense, net   7,504       7,556       22,884       19,115    
Income tax (benefit) expense   (1,118 )     (552 )     (7,598 )     4,068    
Depreciation and amortization expense   5,304       7,152       15,926       20,951    
EBITDA $ (9,064 )   $ (8,770 )   $ 601     $ (18,136 )  
Restructuring, contract termination, impairment and related
charges
  6,211       1,940       9,835       18,030    
Business optimization and expansion expense   274       788       488       4,341    
Equity-based compensation expense   392       861       1,520       895    
Changes in fair value of contingent earn-out liability   —       —       —       (787 )  
Management transition costs   —       88       —       208    
Transaction costs   46       (25 )     522       (25 )  
Costs associated with the refinancing amendment   —       —       —       4,341    
Adjusted EBITDA $ (2,141 )   $ (5,118 )   $ 12,966     $ 8,867    
                 
Net income (loss) margin (Net income (loss) as a % of net
sales)
  (47.5 )%     (43.2 )%     (15.7 )%     (28.0 )%  
                 
Adjusted EBITDA margin (Adjusted EBITDA as a % of net
sales)
  (4.9 )%     (9.6 )%     6.6 %     4.0 %  

  • Compass Lexecon receives Competition Economics Firm of the Year for 12th consecutive year
  • FTI Consulting receives Consulting Firm of the Year for 10th consecutive year
  • Compass Lexecon experts named Energy Expert of the Year and Mining Expert of the Year

WASHINGTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that the firm, its Compass Lexecon subsidiary and their experts were recognized as industry leaders at the 2026 Lexology Index Awards, receiving 17 honors.

FTI Consulting won Consulting Firm of the Year for the 10th consecutive year and remains the only firm to receive the award since it launched in 2017. Compass Lexecon earned Competition Economics Firm of the Year for the 12th year running, also the sole winner since that award began in 2015.

FTI Consulting CEO and Chairman Steven H. Gunby said, “The fact that Compass Lexecon and FTI Consulting have received these awards each year since their inception speaks to the expertise of our world-class professionals; it reflects our ongoing commitment to attracting and supporting the sort of professionals that clients turn to when they face highly complex, high-stakes challenges. That leading expertise in turn is what makes us the firm organizations call in moments of crisis and transformation.”

FTI Consulting was recognized in the following Firm of the Year categories:

  • Consulting Firm of the Year
  • Commercial Litigation Expert Firm of the Year
  • Energy Experts Firm of the Year
  • Insurance Expert Witnesses Firm of the Year
  • Investigations Digital Forensics Firm of the Year
  • Investigations Forensic Accounting Firm of the Year
  • Restructuring & Insolvency Advisers Firm of the Year

FTI Consulting was also recognized with Lexology Index awards for exceptional expertise in the following countries:

  • Australia
  • Cayman Islands
  • England
  • France
  • Germany
  • USA

In addition to Competition Economics Firm of the Year, Compass Lexecon received the Spain Experts Country Award. The following Compass Lexecon professionals also received individual recognitions:

  • Boaz Moselle, Executive Vice President – Energy Expert of the Year
  • Carla Chavich, Executive Vice President – Mining Expert of the Year

Earlier this year, Compass Lexecon topped the Lexology Index: Competition 2026 list for global economic consulting firms, with 65 professionals named. In addition, nine FTI Consulting professionals were named to the list, which identifies individual experts who are considered to be the best consultants, expert witnesses and advisers in the world, and are highlighted for their expert knowledge and testimony in complex antitrust matters and competition economics.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,200 employees located in 32 countries and territories as of September 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

About Compass Lexecon
Compass Lexecon is internationally recognized as a leading economic consulting firm with preeminent competition, finance, intellectual property, international arbitration, and energy practices. With more than 600 professionals in 23 offices around the world, Compass Lexecon offers a global perspective on economic matters. For the past two decades, Compass Lexecon has been ranked as one of the leading antitrust economics firms in the world by the Global Competition Review. To learn more about Compass Lexecon or to find one of our professionals, please visit www.compasslexecon.com.

FTI Consulting, Inc.
555 12th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:
Sam Ford
+1.617.480.7402
samantha.ford@fticonsulting.com

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff

Completed BLA-enabling PPQ manufacturing campaign for TSHA-102, which met predefined product specifications as well as comparability criteria for commercial product and clinical material, supporting potential inclusion of REVEAL Part A Phase 1/2 data in the planned BLA

Encore data supporting TSHA-102 clinical program presented at the 55th Child Neurology Society Annual Meeting

Conference call and webcast today at 8:30 AM ET

DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome. In parallel, we achieved an important manufacturing milestone with the successful completion of our BLA-enabling PPQ manufacturing campaign, which met the predefined acceptance and comparability criteria previously reviewed with FDA. Importantly, the results further demonstrated our ability to consistently manufacture high-quality product at commercial scale, including an encouraging single-digit empty capsid percentage, a key indicator of product quality that contributes to patient safety. Looking ahead, we believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway, and the anticipated nomination of a second gene therapy development program with a high unmet medical need and robust commercial opportunity as we begin building a broader CNS genetic medicine franchise.”

Recent Corporate and TSHA-102 Program Highlights

  • REVEAL Pivotal and ASPIRE Trials Ongoing with TSHA-102 Continued to be Generally Well-Tolerated. High dose (1×1015 total vector genomes (vg)) and low dose (5.7×1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff. All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.
  • Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102. Following alignment on the company’s proposed PPQ strategy with the U.S. Food and Drug Administration (FDA), Taysha completed its Biologics License Application (BLA)-enabling PPQ manufacturing campaign for TSHA-102, including the successful production of commercial-scale drug product batches required to validate the final commercial manufacturing process in support of a potential BLA submission and future commercialization of TSHA-102.
    • All process parameters and analytical results met predefined product specifications as well as comparability criteria for commercial product and clinical material. Together with the comparability of the clinical material used across the REVEAL Part A and Part B pivotal trials, these results support the potential inclusion of REVEAL Part A data in the planned BLA submission.
    • The final TSHA-102 commercial manufacturing process consistently achieved a single-digit empty capsid percentage, an important indicator of product quality that contributes to patient safety. The PPQ results also demonstrate the process consistency and scalability required to support potential commercial demand. The Company plans to discuss these Chemistry Manufacturing and Controls (CMC) data in an anticipated meeting with FDA in the fourth quarter of 2026 to further strengthen the CMC package for the potential BLA submission.
  • Showcased Multiple Encore Presentations Supporting TSHA-102 Clinical Program at the 55th Child Neurology Society Annual Meeting. One oral presentation and three poster presentations were delivered at the 55th Child Neurology Society Annual Meeting. The presentations, available on the Company’s website, highlighted data previously presented at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.

Anticipated Milestones

  • FDA feedback following CMC Type B meeting expected in the first quarter of 2027
  • Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027
  • Expect to nominate an additional gene therapy development candidate targeting a CNS disorder with high unmet need and commence preclinical development activities in the first half of 2027

Third Quarter 2026 Financial Highlights 

Research and Development Expenses: Research and development expenses were $28.8 million for the three months ended September 30, 2026, compared to $25.7 million for the three months ended September 30, 2025. The $3.1 million increase was primarily driven by higher clinical expenses from the REVEAL Part A Phase 1/2, REVEAL Part B pivotal and ASPIRE trials. Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.

General and Administrative Expenses: General and administrative expenses were $13.1 million for the three months ended September 30, 2026, compared to $8.3 million for the three months ended September 30, 2025. The increase of $4.8 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net Loss: Net loss for the three months ended September 30, 2026, was $39.1 million, or $0.10 per share, compared to a net loss of $32.7 million, or $0.09 per share, for the three months ended September 30, 2025.

Cash and Cash Equivalents: As of September 30, 2026, Taysha had $422.8 million in cash and cash equivalents. The Company expects that its current cash resources will support planned operating expenses and capital requirements into the second half of 2028.

Conference Call and Webcast Information
Taysha management will host a live conference call and webcast today at 8:30 a.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.

About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, Taysha’s manufacturing and commercial readiness activities, Taysha’s anticipated nomination of a second gene therapy development program with a high unmet medical need and strong commercial opportunity, and the ability of Taysha’s current cash resources to support planned operating expenses into the second half of 2028. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

 
Taysha Gene Therapies, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
 
    For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
      2026       2025       2026       2025  
Revenue   $ —     $ —     $ —     $ 4,288  
Operating expenses:                
Research and development   28,766       25,745       101,211       61,451  
General and administrative   13,106       8,279       34,929       25,035  
Net gain on lease termination   —       —       (3,433 )     —  
Total operating expenses     41,872       34,024       132,707       86,486  
Loss from operations     (41,872 )     (34,024 )     (132,707 )     (82,198 )
Other income (expense):                
Change in fair value of warrant liability   —       (292 )     —       (463 )
Change in fair value of term loan   (1,087 )     (1,534 )     (4,078 )     (4,525 )
Interest income     3,903       3,169       8,814       6,354  
Interest expense     (4 )     (15 )     (19 )     (51 )
Other expense     (68 )     (37 )     (187 )     (261 )
Total other income (expense), net   2,744       1,291       4,530       1,054  
Net loss   $ (39,128 )   $ (32,733 )   $ (128,177 )   $ (81,144 )
Net loss per common share, basic and diluted $ (0.10 )   $ (0.09 )   $ (0.34 )   $ (0.26 )
Weighted average common shares outstanding, basic and diluted   406,106,872       353,309,524       380,739,173       307,175,982  

 
Taysha Gene Therapies, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands, except share and per share data)
 
    September 30,
2026
  December 31,
2025
ASSETS        
Current assets:        
Cash and cash equivalents   $ 422,834     $ 319,767  
Restricted cash     —       449  
Prepaid expenses and other current assets     3,221       4,431  
Total current assets     426,055       324,647  
Restricted cash     165       2,315  
Property, plant and equipment, net     2,526       6,736  
Operating lease right-of-use assets     6,236       9,439  
Other non-current assets     48       183  
Total assets   $ 435,030     $ 343,320  
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable   $ 5,592     $ 6,275  
Accrued expenses and other current liabilities     17,358       20,277  
Total current liabilities     22,950       26,552  
Term loan, net     47,331       50,106  
Operating lease liability, net of current portion     6,104       18,172  
Other non-current liabilities     1,673       1,552  
Total liabilities     78,058       96,382  
Commitments and contingencies – Note 13        
Stockholders’ equity        
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2026, and December 31, 2025     —       —  
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,883,280 and 285,051,648 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     3       3  
Additional paid-in capital     1,194,098       958,427  
Accumulated other comprehensive income (loss)     2,348       (192 )
Accumulated deficit     (839,477 )     (711,300 )
Total stockholders’ equity     356,972       246,938  
Total liabilities and stockholders’ equity   $ 435,030     $ 343,320  
                 

Company Contact:
investors@tayshagtx.com

Media Contact:
Media@tayshagtx.com

Global PERFORMA Phase 3 trial in MASH progressing as planned

Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation
at AASLD The Liver Meeting® 2026

End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026

$480 million in cash, cash equivalents and investments as of September 30, 2026

Webcast to be held today at 8:30 a.m. ET

MORRISTOWN, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “Our global PERFORMA Phase 3 trial in MASH is ramping up, and we are very encouraged by the progress to date and the enthusiasm we see from the MASH community. In AUD, we look forward to engaging with the FDA in an End-of-Phase 2 meeting where we will leverage our strong RECLAIM data to discuss a Phase 3 registrational program. Following the recent AASLD meeting, our conviction in pemvidutide’s potential is stronger than ever, as we focus on delivering meaningful benefit to patients with serious liver diseases.”

Key Highlights and Anticipated Milestones

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • Pemvidutide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on 24-week data from the IMPACT Phase 2b trial
  • IMPACT Phase 2b 48-week data published in The Lancet Gastroenterology & Hepatology in a paper titled “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study”
  • The global PERFORMA Phase 3 MASH trial is progressing as planned
  • The PERFORMA 52-week topline data readout is anticipated in 2029

Alcohol Use Disorder (AUD)

  • Pemvidutide was granted Fast Track designation by the FDA for the treatment of AUD
  • An End-of-Phase 2 meeting with the FDA is scheduled for December 2026 to discuss the Phase 3 registrational program in AUD

Alcohol-associated Liver Disease (ALD)

  • Enrollment is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027

Scientific Data on Pemvidutide in MASH and AUD Presented at AASLD The Liver Meeting® 2026

  • A late-breaking oral presentation: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo Controlled Trial on the RECLAIM Phase 2 data in AUD was delivered by Dr. Henry R. Kranzler, University of Pennsylvania Perelman School of Medicine
  • An oral presentation: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis was delivered by Dr. Naim Alkhouri, Summit Clinical Research
  • A poster presentation: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial
  • An oral presentation: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model

Corporate Updates

  • In October 2026, the Company appointed Peter Greenleaf and Alex Howarth to the Board of Directors to support its strategic evolution
  • In November 2026, the Company relocated its corporate headquarters to Morristown, New Jersey

Financial Results for the Three Months Ended September 30, 2026

  • Altimmune reported cash, cash equivalents and investments totaling $480 million as of September 30, 2026
  • Research and development (R&D) expenses were $27.0 million for the three months ended September 30, 2026, compared to $15.0 million in the same period in 2025, with the increase driven primarily by the ongoing PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD. R&D expenses for the quarter ended September 30, 2026, included $20.3 million in direct costs related to pemvidutide development activities
  • General and administrative (G&A) expenses were $8.7 million for the three months ended September 30, 2026, compared to $5.9 million in the same period in 2025. The increase was driven primarily by an increase in compensation expenses and professional services
  • Interest income was $4.8 million for the three months ended September 30, 2026
  • Net loss for the three months ended September 30, 2026, was $31.6 million, or $0.15 net loss per share, compared to a net loss of $19.0 million, or $0.21 net loss per share, in the same period in 2025

Conference Call Information:

Date:  November 12, 2026
Time:  8:30 a.m. Eastern Time

Webcast: To listen, the conference call will be webcast live on Altimmune’s Investor Relations (IR) website at https://ir.altimmune.com/investors.
Dial-in: To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call.

Following the conclusion of the call, the webcast will be available for replay on the IR page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is a novel, investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH, was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

About Altimmune 

Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD).For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Forward-Looking Statements
Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including the ongoing PERFORMA and RESTORE trials, the timing of key milestones for the Company’s clinical programs, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Company’s financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, and the impact of the changes to our leadership and governance structure, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy;  the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with the SEC, which are available at www.sec.gov.

Investor Contact:
Luis Sanay, CFA
ir@altimmune.com

Media Contact:
Marisa Sharkey
media@altimmune.com

ALTIMMUNE, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per-share amounts)

             
    September 30,   December 31,
    2026     2025  
    (Unaudited)      
ASSETS            
Current assets:            
Cash and cash equivalents   $ 28,888     $ 43,760  
Restricted cash     42       42  
Total cash, cash equivalents and restricted cash     28,930       43,802  
Short-term investments     236,171       229,696  
Accounts and other receivables     3,661       1,219  
Income tax and R&D incentive receivables     —       518  
Prepaid expenses and other current assets     7,008       2,957  
Total current assets     275,770       278,192  
Long-term investments     214,823       —  
Property and equipment, net     112       312  
Other assets     4,941       1,425  
Total assets   $ 495,646     $ 279,929  
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities:            
Accounts payable   $ 767     $ 2,717  
Accrued expenses and other current liabilities     10,759       12,280  
Total current liabilities     11,526       14,997  
Term loan, noncurrent     34,989       34,287  
Other noncurrent liabilities     5,565       5,753  
Total liabilities     52,080       55,037  
Stockholders’ equity:            
Common stock, $0.0001 par value; 400,000,000 and 200,000,000 shares authorized; 194,537,875 and 110,882,735 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     19       11  
Additional paid-in capital     1,178,044       879,292  
Accumulated deficit     (726,479 )     (649,483 )
Accumulated other comprehensive loss, net     (8,018 )     (4,928 )
Total stockholders’ equity     443,566       224,892  
Total liabilities and stockholders’ equity   $ 495,646     $ 279,929  


ALTIMMUNE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except share and per-share amounts)

                         
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2026     2025     2026     2025  
Revenues   $ —     $ 5     $ —     $ 15  
Operating expenses:                        
Research and development     27,016       14,960       61,863       48,023  
General and administrative     8,689       5,904       24,315       17,588  
Total operating expenses     35,705       20,864       86,178       65,611  
Loss from operations     (35,705 )     (20,859 )     (86,178 )     (65,596 )
Other income (expense):                        
Interest expense     (1,121 )     (495 )     (3,286 )     (760 )
Interest income     4,819       2,426       12,246       5,103  
Other income (expense), net     399       (86 )     222       (163 )
Total other income (expense), net     4,097       1,845       9,182       4,180  
Net loss before income taxes     (31,608 )     (19,014 )     (76,996 )     (61,416 )
Income tax expense (benefit)     —       —       —       (681 )
Net loss     (31,608 )     (19,014 )     (76,996 )     (60,735 )
Other comprehensive income — unrealized (loss) gain on investments     (1,980 )     23       (3,090 )     (43 )
Comprehensive loss   $ (33,588 )   $ (18,991 )   $ (80,086 )   $ (60,778 )
Net loss per share, basic and diluted   $ (0.15 )   $ (0.21 )   $ (0.45 )   $ (0.74 )
Weighted-average common shares outstanding, basic and diluted     205,273,395       89,418,028       172,016,738       82,198,581  

Company to report third quarter 2026 financial results and host conference call at 8:30 a.m. ET

HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced it will host a conference call on Monday, November 16, 2026, at 8:30 a.m. Eastern Time to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide® commercial update. The Company will also report its third quarter 2026 financial results that day.

Webcast and Conference Call
Date/Time: Monday, November 16, 2026, at 8:30 AM ET
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=vTAb1pUs
Dial-in: U.S.: 833-862-0853
  International: 412-365-5147
  Please dial in 15 minutes prior to the start time.
   

Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days.

About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS. 

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. 

By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Investor Contact
CORE IR
IR@cerenome.com

LOUISVILLE, Ky., Nov. 12, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced that it has signed Toyota Motor Corporation’s Canadian dealerships, covering the Toyota and Lexus brands, to an exclusive five-year Master Services Agreement (MSA). As part of this contract, the Company will convert and manage the existing digital signage network in more than 117 Toyota and Lexus dealerships across the country, deploy new screens in locations that do not yet have digital signage, and create English and French content. In total, the agreement covers approximately 280 Toyota and Lexus dealerships in Canada; work is expected to begin in the fourth quarter of 2026, with all initial conversions/installations to be complete by the end of 2027.

“We are extremely pleased to announce a significant, long-term exclusive agreement with Toyota of Canada,” said Rick Mills, Chief Executive Officer. “Covering almost 300 dealerships across the nation, this contract, to be rolled out in phases, will completely change the shopping experience for millions of people in and outside the showroom. While adding new screens is part of the program, the real value of the partnership is enhanced content – as customers are educated and entertained on the sales floor, in the lounge, and throughout the dealership, supporting all employee interaction. Creative Realities will be responsible for all content, network operations, and on-site support. It’s a great opportunity for us to demonstrate our unique, innovative capabilities to a marque client while increasing our ARR, or Annualized Recurring Revenue. We look forward to building on this important relationship in the quarters to come.”

About Creative Realities, Inc.
Creative Realities designs, develops and deploys digital signage-based experiences for enterprise-level networks utilizing its Clarity™, ReflectView™, and iShowroom™ Content Management System (CMS) platforms. The Company is actively providing recurring SaaS and support services across diverse vertical markets, including, but not limited to, retail, automotive, digital out-of-home (DOOH) advertising networks, convenience stores, foodservice/QSR, gaming, theater, and stadium venues. In addition, the Company assists clients in utilizing place-based digital media to achieve business objectives such as increased revenue, enhanced customer experiences, and improved productivity. This includes the design, deployment, and day-to-day management of retail media networks to monetize on-premise foot traffic utilizing its AdLogic™ and CPM+™ programmatic advertising platforms.

Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and includes, among other things, discussions of our business strategies, product releases, future operations and capital resources. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance, conditions or results. They are based on the opinions, estimates and beliefs of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors, many of which are outside of our control, that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Some of these risks are discussed in the “Risk Factors” section contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent filings with the U.S. Securities and Exchange Commission. Important factors, among others, that may affect actual results or outcomes include: our ability to integrate the acquired business operations of Cineplex Digital Media Inc. (“CDM”) into our own, maintain or improve the financial performance of CDM’s business and realize anticipated synergies, our strategy for customer retention, growth, product development, market position, financial results and reserves, our ability to execute on our business plan, our ability to retain key personnel, our ability to remain listed on the Nasdaq Capital Market, our ability to realize the revenues included in our future guidance and backlog reports, our ability to satisfy our upcoming debt obligations and other liabilities, the ability of the Company to continue as a going concern, potential litigation, supply chain shortages, and general economic and market conditions impacting demand for our products and services. Readers should not place undue reliance upon any forward-looking statements. We assume no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Media:
Idea Grove
creativerealities@ideagrove.com 

Investor Relations:
Chris Witty
cwitty@darrowir.com
646-438-9385

ir@cri.com
https://investors.cri.com/

– Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic thyroid cancer (ATC), a highly aggressive cancer with significant unmet need commonly driven by BRAF or RAS mutations –

– IND submission planned by year-end 2026, with first patient dosing targeted for mid-2027; study is designed to be potentially registrational –

– Preclinical data supporting the rationale for atebimetinib + chemotherapy in ATC to be presented at the 38th EORTC-NCI-AACR Symposium on November 18, 2026 –

– Aligns with Immuneering’s strategy to provide a broad population of cancer patients with important new treatment options –

– Company to hold investor webcast today at 8:30am EST, to discuss both of today’s news announcements; including its clinical development plans in anaplastic thyroid cancer and the collaboration to evaluate CLDN18.2 programs in combination with atebimetinib for pancreatic cancer –

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced plans to initiate a Phase 2 clinical trial evaluating atebimetinib in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC), a highly aggressive form of thyroid cancer with significant unmet need, commonly driven by BRAF or RAS mutations.

Immuneering plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the program by the end of 2026. Subject to regulatory clearance, Immuneering currently expects to dose the first patient in the study in mid-2027, with topline results potentially available 12-18 months after dosing begins. The preliminary study plan is to enroll approximately 60 patients with ATC who progressed on standard of care, including an all-comers cohort and a BRAF V600E cohort. The study is designed to be potentially registrational, pending discussion with regulators.

ATC is one of the fastest growing and most aggressive forms of cancer. While it accounts for a small percentage of all thyroid cancers, its rapid progression and poor prognosis result in a disproportionately high share of thyroid cancer-related deaths. It is commonly driven by the MAPK pathway. BRAF mutations are the most frequently occurring alterations, and the majority of patients have tumors driven by either BRAF mutations or RAS mutations. New treatment options capable of delivering durable tumor control while maintaining tolerability are urgently needed.

“Anaplastic thyroid cancer remains one of the most challenging malignancies we encounter, with tumors that can progress extraordinarily quickly and limited treatment options for many patients,” said Alan Ho, M.D., Ph.D., Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. “Despite important advances for certain molecularly defined subsets of patients, there remains a substantial need for new therapeutic approaches that can provide durable disease control for a broader population of patients with ATC.”

“Atebimetinib has the potential to help patients with many different types of cancer, and to be synergistic in many different combinations,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “The exciting results we have observed to date with atebimetinib in combination with chemotherapy in pancreatic cancer has reinforced our conviction in this approach. With MAPK pathway activation a defining feature of anaplastic thyroid cancer, and BRAF and RAS mutations among its key drivers, deep cyclic inhibition of MAPK signaling with atebimetinib represents an innovative, promising therapeutic approach in combination with chemotherapy for addressing the significant unmet need in anaplastic thyroid cancer. We are grateful to the esteemed group of world-class thyroid cancer experts who have helped design this study and encouraged us to pursue it with a high degree of optimism, and together we are moving full speed ahead.”

The scientific rationale supporting the planned clinical program will be highlighted in a preclinical poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20, 2026, in Barcelona, Spain.

Poster Presentation Details:
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC).
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair
Date: Wednesday, November 18, 2026

Following presentation, the poster is expected to be available on the publications section of Immuneering’s website.

Conference Call
Immuneering will host a conference call and live webcast at 8:30 a.m. EST on November 12, 2026, to discuss today’s news announcements. Individuals interested in listening to the live conference call may do so by dialing (800) 715-9871 for U.S. callers and (646) 307-1963 for other locations and reference conference ID 6087332, or from the webcast link in the “investors” section of the company’s website at www.immuneering.com. A webcast replay will be available in the investor relations section on the company’s website for 90 days following the completion of the call.

About Anaplastic Thyroid Cancer
Anaplastic thyroid cancer, or ATC, is a rare and highly aggressive form of thyroid cancer characterized by rapid tumor growth and invasion into surrounding tissues. According to the National Cancer Institute, ATC accounts for approximately 1% to 2% of thyroid cancer cases and affects approximately one to two people per million each year in the United States. Unlike most other forms of thyroid cancer, ATC can progress extremely rapidly and frequently presents with locally advanced or metastatic disease. Standard of care chemotherapy remains a primary treatment option for ATC, however these cytotoxic agents can induce MAPK reactivation, potentially limiting response durability. Although advances in targeted therapies have improved outcomes for some patients with specific molecular alterations, there remains a substantial unmet need for new treatment approaches capable of providing durable disease control across a broader population of patients with ATC.

About Atebimetinib
Atebimetinib is the first in a new category of oral drug candidates, Deep Cyclic Inhibitors (DCIs), designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Each of these mechanisms has been well established to improve survival in published studies. DCIs challenge the conventional model of sustained or continuous inhibition in oncology. Whereas most therapies are designed for sustained inhibition, driving cancer to adapt and develop resistance so tumors shrink quickly but temporarily, DCIs are designed to pulse faster than tumors can adapt, so tumors shrink slowly but durably. Moreover, DCIs aim to restore full transient signaling to healthy cells, with the goal of leading to fewer adverse events. Atebimetinib targets MEK, a key control point in the MAPK pathway (RAS-RAF-MEK-ERK), which is pathologically activated in a majority of cancers, including approximately 97% of pancreatic cancers. Targeting MEK blocks a broader range of MAPK pathway alterations because it is further downstream, creating the potential for more durable benefit.

About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat a wide range of cancers, including in combination with chemotherapy in ATC; the ability of atebimetinib to be synergistic in many different combinations; the significant unmet need in ATC; the Phase 2 study design for ATC, the timing of submission of the IND and regulatory clearance, dosing of patients and availability of topline results for such study; the potential of the Phase 2 study in ATC to be registrational; and that preclinical data demonstrating efficacy in ATC models may translate into human clinical trial data.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory clearance or approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com

Media Contact:
David Caouette
dcaouette@immuneering.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.